- Home
- SAFT vs MESO Comparison
SAFT vs MESO Comparison
Compare SAFT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- MESO
- Stock Information
- Founded
- SAFT 1979
- MESO 2004
- Country
- SAFT United States
- MESO Australia
- Employees
- SAFT N/A
- MESO N/A
- Industry
- SAFT Property-Casualty Insurers
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAFT Finance
- MESO Health Care
- Exchange
- SAFT Nasdaq
- MESO Nasdaq
- Market Cap
- SAFT 1.3B
- MESO 1.2B
- IPO Year
- SAFT N/A
- MESO N/A
- Fundamental
- Price
- SAFT $82.12
- MESO $14.63
- Analyst Decision
- SAFT
- MESO Strong Buy
- Analyst Count
- SAFT 0
- MESO 4
- Target Price
- SAFT N/A
- MESO $13.50
- AVG Volume (30 Days)
- SAFT 68.1K
- MESO 512.2K
- Earning Date
- SAFT 11-05-2024
- MESO 08-28-2024
- Dividend Yield
- SAFT 4.36%
- MESO N/A
- EPS Growth
- SAFT 139.36
- MESO N/A
- EPS
- SAFT 5.07
- MESO N/A
- Revenue
- SAFT $1,091,694,000.00
- MESO $5,902,000.00
- Revenue This Year
- SAFT N/A
- MESO $66.05
- Revenue Next Year
- SAFT N/A
- MESO $348.27
- P/E Ratio
- SAFT $16.18
- MESO N/A
- Revenue Growth
- SAFT 21.41
- MESO N/A
- 52 Week Low
- SAFT $71.99
- MESO $1.61
- 52 Week High
- SAFT $90.00
- MESO $19.15
- Technical
- Relative Strength Index (RSI)
- SAFT 40.23
- MESO 64.37
- Support Level
- SAFT $84.00
- MESO $12.20
- Resistance Level
- SAFT $84.28
- MESO $19.15
- Average True Range (ATR)
- SAFT 1.65
- MESO 0.98
- MACD
- SAFT -0.48
- MESO 0.37
- Stochastic Oscillator
- SAFT 11.21
- MESO 48.93
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.